Literature DB >> 22490456

Unusually high alanine aminotransferase to aspartate aminotransferase ratio in a patient with cyproterone-induced icteric hepatitis.

Yu-Chen Hsu1, Dar-In Tai.   

Abstract

A 70-year-old man with prostatic adenocarcinoma received cyproterone acetate 200 mg per day. Three months later, mild fatigue and anorexia with elevation of the alanine aminotransferase (ALT) level to 1311 U/L, total bilirubin level to 14 mg/dL and prothrombin time of 15/11.9 seconds developed. At that time the aspartate aminotransferase (AST) level was only 82 U/L. Viral hepatitis and autoimmune markers were all negative. This hepatitis resolved quickly after cyproterone therapy was discontinued. One and a half years later, the patient was prescribed cyproterone 100 mg daily at another hospital where staff were unaware of his previous history. General malaise, upper abdominal pain and jaundice developed two months later. Laboratory studies at emergency room revealed an AST of 245 U/L, ALT of 255 U/L, total bilirubin of 8.2 mg/dL, amylase of 6055 U/L, prothrombin time of 15.2/11.1 seconds and platelet count of 68000 cells/mL. Although cyproterone was discontinued, the patient died of multiple organ failure 20 days after admission. This case report presents a rare situation with marked elevation of the ALT level without AST level elevation. This finding suggests that cyproterone may induce specific damage to the plasma membrane, and the mitochondria are not involved in the initial stage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22490456

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  2 in total

1.  Hepatic failure induced by cyproterone acetate: A case report and literature review.

Authors:  Jae Heon Kim; Byung Wook Yoo; Won Jae Yang
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

Review 2.  The de ritis ratio: the test of time.

Authors:  Mona Botros; Kenneth A Sikaris
Journal:  Clin Biochem Rev       Date:  2013-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.